Literature DB >> 19653335

Post-infectious irritable bowel syndrome.

Marroon Thabane1, John K Marshall.   

Abstract

Post-infectious irritable bowel syndrome (PI-IBS) is a common disorder wherein symptoms of IBS begin after an episode of acute gastroenteritis. Published studies have reported incidence of PI-IBS to range between 5% and 32%. The mechanisms underlying the development of PI-IBS are not fully understood, but are believed to include persistent sub-clinical inflammation, changes in intestinal permeability and alteration of gut flora. Individual studies have suggested that risk factors for PI-IBS include patients' demographics, psychological disorders and the severity of enteric illness. However, PI-IBS remains a diagnosis of exclusion with no specific disease markers and, to date, no definitive therapy exists. The prognosis of PI-IBS appears favorable with spontaneous and gradual resolution of symptoms in most patients.

Entities:  

Mesh:

Year:  2009        PMID: 19653335      PMCID: PMC2721231          DOI: 10.3748/wjg.15.3591

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  71 in total

1.  A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome.

Authors:  K D Bardhan; G Bodemar; H Geldof; E Schütz; A Heath; J G Mills; L A Jacques
Journal:  Aliment Pharmacol Ther       Date:  2000-01       Impact factor: 8.171

Review 2.  Probiotics and irritable bowel syndrome: rationale, mechanisms, and efficacy.

Authors:  Michael Camilleri
Journal:  J Clin Gastroenterol       Date:  2008-09       Impact factor: 3.062

3.  Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial.

Authors:  M Camilleri; A R Northcutt; S Kong; G E Dukes; D McSorley; A W Mangel
Journal:  Lancet       Date:  2000-03-25       Impact factor: 79.321

4.  A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.

Authors:  Lin Chang; Vanessa Z Ameen; George E Dukes; David J McSorley; Eric G Carter; Emeran A Mayer
Journal:  Am J Gastroenterol       Date:  2005-01       Impact factor: 10.864

5.  Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients.

Authors:  R H Jones; G Holtmann; L Rodrigo; R S Ehsanullah; P M Crompton; L A Jacques; J G Mills
Journal:  Aliment Pharmacol Ther       Date:  1999-11       Impact factor: 8.171

6.  Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario.

Authors:  J K Marshall; M Thabane; A X Garg; W Clark; J Meddings; S M Collins
Journal:  Aliment Pharmacol Ther       Date:  2004-12       Impact factor: 8.171

7.  Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation.

Authors:  S Müller-Lissner; G Holtmann; P Rueegg; G Weidinger; H Löffler
Journal:  Aliment Pharmacol Ther       Date:  2005-01-01       Impact factor: 8.171

8.  Post-infectious irritable bowel syndrome in patients with Shigella infection.

Authors:  Sangwon Ji; Hyojin Park; Dokyong Lee; Young Koo Song; Jae Phil Choi; Sang-In Lee
Journal:  J Gastroenterol Hepatol       Date:  2005-03       Impact factor: 4.029

9.  The clinical course of postinfectious irritable bowel syndrome: a five-year follow-up study.

Authors:  In Su Jung; Hee Sun Kim; Hyojin Park; Sang In Lee
Journal:  J Clin Gastroenterol       Date:  2009-07       Impact factor: 3.062

Review 10.  The use of probiotics in the prevention and treatment of antibiotic-associated diarrhea with special interest in Clostridium difficile-associated diarrhea.

Authors:  Cynthia L Rohde; Vickie Bartolini; Nicole Jones
Journal:  Nutr Clin Pract       Date:  2009 Feb-Mar       Impact factor: 3.080

View more
  52 in total

Review 1.  What does irritable bowel syndrome share with non-alcoholic fatty liver disease?

Authors:  Antonella Scalera; Matteo Nicola Dario Di Minno; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

Review 2.  Early child growth: how do nutrition and infection interact?

Authors:  Kathryn G Dewey; Daniel R Mayers
Journal:  Matern Child Nutr       Date:  2011-10       Impact factor: 3.092

Review 3.  Post-Infectious Irritable Bowel Syndrome.

Authors:  Yeong Yeh Lee; Chandramouli Annamalai; Satish S C Rao
Journal:  Curr Gastroenterol Rep       Date:  2017-09-25

Review 4.  Irritable bowel syndrome: common integrative medicine perspectives.

Authors:  Richard Nahas
Journal:  Chin J Integr Med       Date:  2011-06-10       Impact factor: 1.978

Review 5.  Irritable bowel syndrome: a gut microbiota-related disorder?

Authors:  Yogesh Bhattarai; David A Muniz Pedrogo; Purna C Kashyap
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-11-23       Impact factor: 4.052

6.  Chronic diarrhea in travelers.

Authors:  Bradley A Connor
Journal:  Curr Infect Dis Rep       Date:  2013-06       Impact factor: 3.725

7.  New and Emerging Treatment Options for Irritable Bowel Syndrome.

Authors:  Brian E Lacy; William D Chey; Anthony J Lembo
Journal:  Gastroenterol Hepatol (N Y)       Date:  2015-04

Review 8.  Neuroanatomy of lower gastrointestinal pain disorders.

Authors:  Wim Vermeulen; Joris G De Man; Paul A Pelckmans; Benedicte Y De Winter
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

Review 9.  Complementary and alternative medicines in irritable bowel syndrome: an integrative view.

Authors:  Oliver Grundmann; Saunjoo L Yoon
Journal:  World J Gastroenterol       Date:  2014-01-14       Impact factor: 5.742

10.  Antimicrobial resistance and antimicrobial use associated with laboratory-confirmed cases of Campylobacter infection in two health units in Ontario.

Authors:  Anne E Deckert; Richard J Reid-Smith; Susan E Tamblyn; Larry Morrell; Patrick Seliske; Frances B Jamieson; Rebecca Irwin; Catherine E Dewey; Patrick Boerlin; Scott A McEwen
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.